FDA
-
-
-
-
-
-
-
Guardant Health (GH) PT Raised to $195 at BTIG
-
-
-
-
-
-
-
Guardant Health receives FDA approval for companion diagnostic test
-
-
-
-
-
-
-
American Cancer Society Recommends Guardant Health’s Shield Blood Test in Updated Colorectal Cancer Screening Guidelines
-
-
-
-
-
-
-
Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mu
-
-
-
-
-
-
-
Guardant Health’s Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics
-
-
-
-
-
-
-
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results
-
-
-
-
-
-
-
Guardant Health partners with Quest for blood-based cancer screening
-
334,273 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


